Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre
In this real-world cohort of patients with atopic dermatitis, lebrikizumab demonstrated efficacy comparable to that observed in clinical trials. It may provide an alternative treatment option for individuals who have discontinued other biologics as a result of conjunctivitis.
Authors
- H.J.A. Hunter (ORCID: https://orcid.org/0000-0003-2487-5381)
- Neenu Sebastian (ORCID: https://orcid.org/0009-0008-2775-8192)
- A. Abraheem (ORCID: https://orcid.org/0009-0001-4050-3425)
- Firas C. Kreeshan (ORCID: https://orcid.org/0000-0001-7934-0806)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Timothy Clayton
Institutions
- Manchester Academic Health Science Centre (GB)
- NIHR Manchester Biomedical Research Centre (GB)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1007/s13555-025-01614-9
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00